Link To Us Link To Us

Bookmark Us Bookmark Us

Supplier Login Supplier Login

Linscott's Directory of Immunological & Biological Reagents
CAYMAN CHEMICAL COMPANY
 (http://www.caymanchem.com)

CAYMAN CHEMICAL COMPANY

1180 East Ellsworth Road

Ann Arbor MI 48108

Phone: (734) 971-3335

Phone: (800) 364-9897 (USA & Canada only)

Fax: (734) 971-3640

Customer Service: custserv@caymanchem.com
Technical Support: techserv@caymanchem.com
Sales: sales@caymanchem.com

Website: http://www.caymanchem.com

 
 
CAYMAN CHEMICAL COMPANY Products - Page 194 of 705
Page 194 of 705
Records 4,826 - 4,850 of 17,619
Name Description Size Catalog #
AKB48 N-pentanoic acid metabolite A potential urinary metabolite of AKB48, characterized by carboxylation of the N-alkyl chain; intended for research and forensic applications 5 mg 14224-5
AKB48-d9 An internal standard for the quantification of AKB48 by GC- or LC-MS 1 mg 14677-1
AKB48-d9 An internal standard for the quantification of AKB48 by GC- or LC-MS 500 µg 14677-500
Akt Inhibitor VIII A potent, allosteric inhibitor of Akt1 and Akt2 (IC50 = 58 and 210 nM, respectively) that less effectively blocks Akt3 activity (IC50 = 2.2 µM); cell permeable, blocking insulin regulation of FOXO1 activity at 1 µM in rat hepatoma cells 1 mg 14870-1
Akt Inhibitor VIII A potent, allosteric inhibitor of Akt1 and Akt2 (IC50 = 58 and 210 nM, respectively) that less effectively blocks Akt3 activity (IC50 = 2.2 µM); cell permeable, blocking insulin regulation of FOXO1 activity at 1 µM in rat hepatoma cells 10 mg 14870-10
Akt Inhibitor VIII A potent, allosteric inhibitor of Akt1 and Akt2 (IC50 = 58 and 210 nM, respectively) that less effectively blocks Akt3 activity (IC50 = 2.2 µM); cell permeable, blocking insulin regulation of FOXO1 activity at 1 µM in rat hepatoma cells 5 mg 14870-5
Akt Inhibitor VIII A potent, allosteric inhibitor of Akt1 and Akt2 (IC50 = 58 and 210 nM, respectively) that less effectively blocks Akt3 activity (IC50 = 2.2 µM); cell permeable, blocking insulin regulation of FOXO1 activity at 1 µM in rat hepatoma cells 500 µg 14870-500
Akt Inhibitor X A cell permeable phenoxazine derivative that suppresses IGF-1-stimulated phosphorylation of Akt with an IC50 value of 1-2 µM; inhibits the growth of Rh1, Rh18, and Rh30 cells with IC50 values of 2-5 µM 1 mg 14863-1
Akt Inhibitor X A cell permeable phenoxazine derivative that suppresses IGF-1-stimulated phosphorylation of Akt with an IC50 value of 1-2 µM; inhibits the growth of Rh1, Rh18, and Rh30 cells with IC50 values of 2-5 µM 10 mg 14863-10
Akt Inhibitor X A cell permeable phenoxazine derivative that suppresses IGF-1-stimulated phosphorylation of Akt with an IC50 value of 1-2 µM; inhibits the growth of Rh1, Rh18, and Rh30 cells with IC50 values of 2-5 µM 5 mg 14863-5
AL 34662 A potent 5-HT2 receptor agonist with ocular hypotensive activity; binds to the human and rat 5-HT2 receptors in cerebral cortex homogenates with IC50 values of 1.5 and 0.77 nM, respectively; lowers IOP 25 % at a dose of 100 µg and 33 % at 300 µg at six hours post dose 1 mg 10011546-1
AL 34662 A potent 5-HT2 receptor agonist with ocular hypotensive activity; binds to the human and rat 5-HT2 receptors in cerebral cortex homogenates with IC50 values of 1.5 and 0.77 nM, respectively; lowers IOP 25 % at a dose of 100 µg and 33 % at 300 µg at six hours post dose 10 mg 10011546-10
AL 34662 A potent 5-HT2 receptor agonist with ocular hypotensive activity; binds to the human and rat 5-HT2 receptors in cerebral cortex homogenates with IC50 values of 1.5 and 0.77 nM, respectively; lowers IOP 25 % at a dose of 100 µg and 33 % at 300 µg at six hours post dose 5 mg 10011546-5
AL 34662 A potent 5-HT2 receptor agonist with ocular hypotensive activity; binds to the human and rat 5-HT2 receptors in cerebral cortex homogenates with IC50 values of 1.5 and 0.77 nM, respectively; lowers IOP 25 % at a dose of 100 µg and 33 % at 300 µg at six hours post dose 50 mg 10011546-50
AL 6598 The isopropyl ester prodrug of AL 6556, a PGD2 receptor agonist (Ki = 3.2 µM, EC50 = 0.80 µM); produces a maximum 53% drop in IOP of the ocular hypertensive monkey with a 1 µg dose given twice daily 1 mg 13620-1
AL 6598 The isopropyl ester prodrug of AL 6556, a PGD2 receptor agonist (Ki = 3.2 µM, EC50 = 0.80 µM); produces a maximum 53% drop in IOP of the ocular hypertensive monkey with a 1 µg dose given twice daily 10 mg 13620-10
AL 6598 The isopropyl ester prodrug of AL 6556, a PGD2 receptor agonist (Ki = 3.2 µM, EC50 = 0.80 µM); produces a maximum 53% drop in IOP of the ocular hypertensive monkey with a 1 µg dose given twice daily 5 mg 13620-5
AL 6598 The isopropyl ester prodrug of AL 6556, a PGD2 receptor agonist (Ki = 3.2 µM, EC50 = 0.80 µM); produces a maximum 53% drop in IOP of the ocular hypertensive monkey with a 1 µg dose given twice daily 500 µg 13620-500
AL 8810 AL 8810 is an 11beta-fluoro analog of PGF2alpha which acts as a potent and selective antagonist at the FP receptor.{7398} AL 8810 has weak intrinsic agonist activity on FP receptor preparations in the 200-300 nM range, yet it fully antagonizes the activity of the potent FP receptor agonist fluprostenol at this concentration, with EC50 values of approximately 430 nM. AL 8810 fully antagonized the bimatoprost-induced calcium mobilization in Swiss 3T3 fibroblasts at 100 µM, indicating that bimatoprost acts as an FP agonist in this preparation.{9581} The Ki for the inhibition of several potent agonists at the cloned human ciliary body FP receptor is in the range of 1-2 µM.{10426} 1 mg 16735-1
AL 8810 AL 8810 is an 11beta-fluoro analog of PGF2alpha which acts as a potent and selective antagonist at the FP receptor.{7398} AL 8810 has weak intrinsic agonist activity on FP receptor preparations in the 200-300 nM range, yet it fully antagonizes the activity of the potent FP receptor agonist fluprostenol at this concentration, with EC50 values of approximately 430 nM. AL 8810 fully antagonized the bimatoprost-induced calcium mobilization in Swiss 3T3 fibroblasts at 100 µM, indicating that bimatoprost acts as an FP agonist in this preparation.{9581} The Ki for the inhibition of several potent agonists at the cloned human ciliary body FP receptor is in the range of 1-2 µM.{10426} 10 mg 16735-10
AL 8810 AL 8810 is an 11beta-fluoro analog of PGF2alpha which acts as a potent and selective antagonist at the FP receptor.{7398} AL 8810 has weak intrinsic agonist activity on FP receptor preparations in the 200-300 nM range, yet it fully antagonizes the activity of the potent FP receptor agonist fluprostenol at this concentration, with EC50 values of approximately 430 nM. AL 8810 fully antagonized the bimatoprost-induced calcium mobilization in Swiss 3T3 fibroblasts at 100 µM, indicating that bimatoprost acts as an FP agonist in this preparation.{9581} The Ki for the inhibition of several potent agonists at the cloned human ciliary body FP receptor is in the range of 1-2 µM.{10426} 25 mg 16735-25
AL 8810 AL 8810 is an 11beta-fluoro analog of PGF2alpha which acts as a potent and selective antagonist at the FP receptor.{7398} AL 8810 has weak intrinsic agonist activity on FP receptor preparations in the 200-300 nM range, yet it fully antagonizes the activity of the potent FP receptor agonist fluprostenol at this concentration, with EC50 values of approximately 430 nM. AL 8810 fully antagonized the bimatoprost-induced calcium mobilization in Swiss 3T3 fibroblasts at 100 µM, indicating that bimatoprost acts as an FP agonist in this preparation.{9581} The Ki for the inhibition of several potent agonists at the cloned human ciliary body FP receptor is in the range of 1-2 µM.{10426} 5 mg 16735-5
AL 8810 ethyl amide An analog of AL 8810 in which the C-1 carboxyl group has been modified to an N-ethyl amide analogous to Bimatoprost 1 mg 10010470-1
AL 8810 ethyl amide An analog of AL 8810 in which the C-1 carboxyl group has been modified to an N-ethyl amide analogous to Bimatoprost 10 mg 10010470-10
AL 8810 ethyl amide An analog of AL 8810 in which the C-1 carboxyl group has been modified to an N-ethyl amide analogous to Bimatoprost 25 mg 10010470-25
© 1980 - 2014 Linscott's Directory, Linscott's USA. All rights reserved.